BRPI0413745A - horário mde dosagem para agentes anticancerìgenos erbb2 - Google Patents

horário mde dosagem para agentes anticancerìgenos erbb2

Info

Publication number
BRPI0413745A
BRPI0413745A BRPI0413745-0A BRPI0413745A BRPI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A BR PI0413745 A BRPI0413745 A BR PI0413745A
Authority
BR
Brazil
Prior art keywords
erbb2
mammal
relates
anticancer agents
dosing schedule
Prior art date
Application number
BRPI0413745-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Samit Kumar Bhattacharya
Richard Damian Connell
James Dale Moyer
Jitesh Pranlal Jani
Dennis Alan Roe
Stefanus Johannes Steyn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0413745A publication Critical patent/BRPI0413745A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0413745-0A 2003-08-18 2004-08-06 horário mde dosagem para agentes anticancerìgenos erbb2 BRPI0413745A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
PCT/IB2004/002580 WO2005016347A1 (en) 2003-08-18 2004-08-06 Dosing schedule for erbb2 anticancer agents

Publications (1)

Publication Number Publication Date
BRPI0413745A true BRPI0413745A (pt) 2006-10-24

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413745-0A BRPI0413745A (pt) 2003-08-18 2004-08-06 horário mde dosagem para agentes anticancerìgenos erbb2

Country Status (18)

Country Link
US (1) US20050119288A1 (enExample)
EP (1) EP1658080A1 (enExample)
JP (1) JP2007502807A (enExample)
KR (2) KR20080014144A (enExample)
CN (1) CN1838959A (enExample)
AR (1) AR045268A1 (enExample)
AU (1) AU2004264726A1 (enExample)
BR (1) BRPI0413745A (enExample)
CA (1) CA2536140A1 (enExample)
CO (1) CO5670356A2 (enExample)
IL (1) IL173127A0 (enExample)
MX (1) MXPA06001989A (enExample)
NO (1) NO20061252L (enExample)
RU (1) RU2328287C2 (enExample)
SG (1) SG135193A1 (enExample)
TW (1) TW200522966A (enExample)
WO (1) WO2005016347A1 (enExample)
ZA (1) ZA200600517B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2407473A3 (en) 2002-02-01 2012-03-21 ARIAD Pharmaceuticals, Inc Method for producing phosphorus-containing compounds
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
US7501427B2 (en) * 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
KR100953246B1 (ko) * 2003-08-14 2010-04-16 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
DK1667992T3 (da) 2003-09-19 2007-04-30 Astrazeneca Ab Quinazolinderivater
RS52119B (sr) * 2004-05-06 2012-08-31 Warner-Lambert Company Llc 4-fenilamino-hinazolin-6-il-amidi
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
US20080194596A1 (en) * 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
WO2006138608A2 (en) * 2005-06-16 2006-12-28 Myriad Genetics, Inc. Pharmaceutical compositions and use thereof
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
EA015922B1 (ru) * 2005-11-14 2011-12-30 Ариад Фармасьютикалз, Инк. ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
ATE507224T1 (de) 2005-11-15 2011-05-15 Array Biopharma Inc Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten
EP2010911A4 (en) * 2006-03-31 2009-05-13 Massachusetts Inst Technology TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS
RU2008143554A (ru) * 2006-04-05 2010-05-10 Новартис АГ (CH) Комбинации терапевтических агентов для лечения рака
JP2010509400A (ja) 2006-11-14 2010-03-25 アリアド・ファーマシューティカルズ・インコーポレイテッド 経口処方組成物
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CA2720983A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
KR20100016385A (ko) * 2007-04-10 2010-02-12 미리어드 파마슈티칼스, 인코포레이티드 뇌종양 치료방법
EP2144887A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
ES2417148T3 (es) 2007-06-08 2013-08-06 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
WO2013078440A2 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
EP3101115B1 (en) 2014-01-31 2020-10-21 Toppan Printing Co., Ltd. Biomolecule analysis kit and biomolecule analysis method
EP3368546A4 (en) 2015-10-28 2019-06-26 Tarveda Therapeutics, Inc. AGAINST SSTR CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA932522B (en) * 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE122005000053I2 (de) * 1995-03-30 2008-01-17 Pfizer Prod Inc Chinazolinderivate
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
HUP0301120A2 (hu) * 2000-06-22 2003-08-28 Pfizer Products Inc. Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények
AU2002339687A1 (en) * 2001-12-12 2003-06-23 Pfizer Products Inc. Quinazoline derivatives for the treatement of abnormal cell growth
EA007412B1 (ru) * 2001-12-12 2006-10-27 Пфайзер Продактс Инк. Соли е-2-метокси-n-(3-(4-(3-метилпиридин-3-илокси)фениламино)хиназолин-6-ил-аллил)ацетамида, их получение и их применение против рака
NZ540092A (en) * 2002-11-20 2007-06-29 Array Biopharma Inc Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
CN1729001A (zh) * 2002-12-18 2006-02-01 辉瑞产品公司 用于治疗异常细胞生长的4－苯胺基喹唑啉衍生物

Also Published As

Publication number Publication date
CA2536140A1 (en) 2005-02-24
TW200522966A (en) 2005-07-16
MXPA06001989A (es) 2006-05-17
ZA200600517B (en) 2007-02-28
CN1838959A (zh) 2006-09-27
SG135193A1 (en) 2007-09-28
AR045268A1 (es) 2005-10-19
NO20061252L (no) 2006-05-16
KR20060037447A (ko) 2006-05-03
JP2007502807A (ja) 2007-02-15
WO2005016347A1 (en) 2005-02-24
RU2328287C2 (ru) 2008-07-10
CO5670356A2 (es) 2006-08-31
EP1658080A1 (en) 2006-05-24
KR20080014144A (ko) 2008-02-13
IL173127A0 (en) 2006-06-11
US20050119288A1 (en) 2005-06-02
AU2004264726A1 (en) 2005-02-24
RU2006102125A (ru) 2007-09-27

Similar Documents

Publication Publication Date Title
BRPI0413745A (pt) horário mde dosagem para agentes anticancerìgenos erbb2
DIONNE et al. Suppression of postoperative pain by preoperative administration of ibuprofen in comparison to placebo, acetaminophen, and acetaminophen plus codeine
Argyriou et al. A review on oxaliplatin-induced peripheral nerve damage
Kosharskyy et al. Intravenous infusions in chronic pain management
BR0010524A (pt) Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
BR0110420A (pt) Agonistas muscarìnicos
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
BRPI0413580A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer em um mamìfero em necessidade de tal tratamento, para modular a formação do fuso mitótico e para inibir a cinesina mitótica ksp
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
BR0014166A (pt) Método de utilização de inibidores de reabsorção de serotonina seletivo de rápido ataque para tratamento de disfunção sexual
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BRPI0411608A (pt) derivado de 8-aza-biciclo [3.2.1] octano, composição farmacêutica, uso do composto, e, método de tratamento, prevenção ou alìvio de uma doença, um distúrbio ou uma condição de um organismo animal vivo
BR112022026247A2 (pt) Método para aumentar a eficácia terapêutica de um agente de imunoterapia, método de tratamento de câncer e método de inibição do crescimento de uma célula de câncer
JP2016507493A5 (enExample)
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
Jia et al. CD73 regulates hepatic stellate cells activation and proliferation through Wnt/β-catenin signaling pathway
BRPI0607536A2 (pt) tratamento de dor
Marri Adjuvant agents in regional anaesthesia
Vallejo et al. Preemptive analgesia with bupivacaine for segmental mastectomy
Muriel-Villoria et al. Comparison of the onset and duration of the analgesic effect of dipyrone, 1 or 2 g, by the intramuscular or intravenous route, in acute renal colic

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.